openPR Logo
Press release

Integrase Inhibitors Market Top Players - Gilead Sciences, ViiV Healthcare, Merck & Co., Inc., GlaxoSmithKline PLC.

12-20-2024 08:16 AM CET | Health & Medicine

Press release from: Insightace Analytic Pvt Ltd.

Integrase Inhibitors Market

Integrase Inhibitors Market

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Integrase Inhibitors Market- (By Drug Class (First-Generation Integrase Inhibitors, Second-Generation Integrase Inhibitors, Others), By Indication (HIV Infection, Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals and Clinics, Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Integrase Inhibitors Market is valued at US$ 27.66 Bn in 2022, and it is expected to reach US$ 40.56 Bn by 2031, with a CAGR of 4.5% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2089

Integrase inhibitors are a relatively new family of anti-HIV drugs that prevent the virus from inserting its DNA into the host cell's genome. The growing demand for HIV medications has increased alongside the spread of information about the disease and its prevalence. Access to HIV testing and treatment has increased in recent years, making this especially true in developing nations and is expected to increase in the coming years. The high demand for antiretroviral medications directly results from many people infected with HIV worldwide.

The government is also making efforts to expand HIV testing and treatment options for those who need them. Future integrase inhibitors market growth will be accelerated by sustained economic expansion and the introduction of innovative products. The introduction of novel drugs and sustained economic growth indicate the integrase inhibitors market's future growth. Uneven access to HIV treatment and a lack of education about the disease will hinder the market. The development of regulations grows the market demand for integrase inhibitors and ultimately increases competition, thereby boosting market growth.

List of Prominent Players in the Integrase Inhibitors Market:
• Gilead Sciences
• ViiV Healthcare
• Merck & Co., Inc.
• GlaxoSmithKline PLC
• Bristol-Myers Squibb Company
• Johnson & Johnson
• AbbVie Inc.,
• Janssen
• Pharmaceuticals Inc.
• Theratechnologies Inc.
• Shionogi & Co. Ltd.

Market Dynamics:
Drivers-
Growing demand for integrase inhibitors owing to their rising disposable income, evolving consumer preferences, and the availability of cheaper generic alternatives, etc., is a key factor likely to grow the target market. Increasing healthcare spending contributes to the sector's infrastructural development. The integrase inhibitors market will grow due to developments in medical technology, increased public and private sector efforts to raise awareness, and rising government funding. The growth rate of the integrase inhibitors market will also be influenced favourably by other variables, such as the development of the biotechnology sector and numerous technological breakthroughs, factors expected to augment the growth of the global integrase inhibitors market.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Challenges:
The prime challenge is a lack of awareness of disease management and compliance with medication because of lockdowns and isolation in emerging countries, which is predicted to slow down the growth of the integrase inhibitors market. However, the drug's high price and inadequate healthcare infrastructure are in developing nations. The medication's associated negative effects will also hamper the development of the overall growth of the integrase inhibitors market over the coming years.

The COVID-19 period has caused significant delays in the supply chain, changes in the stock market, and fluctuations in the availability of pharmaceuticals. According to a recent update, the industries are facing unprecedented economic losses due to disruptions in global supply chains for key players operating in the global integrase inhibitors market. Distributors, suppliers and retailers have inventory but can't sell, and manufacturers must stop production to deal with the shutdown.

Regional Trends:
The North American integrase inhibitors market is anticipated to record a maximum market share in revenue, and it is projected to grow at a high CAGR in the near future because there are many people in need of care, a robust healthcare system, growing governmental support for HIV/AIDS medication, and increasing research and development efforts by prominent players are factors estimated to increase the growth of the integrase inhibitors market in the region.

Besides, Europe had a considerable share in the market due to its developed economy, advanced medical facilities and systems. This is due to the adoption of innovative methods by the major players in the integrase inhibitors market. Moreover, the existence of key market players and the growing cooperation between major players for market penetration in the area enables an opportunity to grow the global integrase inhibitors market.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2089

Recent Developments:
• In June 2023, Gilead Sciences, Inc. and Merck recently formed a collaborative agreement to jointly develop and market extended-release therapies for HIV. This partnership involves the combination of Gilead's ongoing research on lenacapavir, a capsid inhibitor, and Merck's ongoing research on islatravir, a nucleoside reverse transcriptase translocation inhibitor. The ultimate goal of this collaboration is to create a two-drug treatment regimen that offers innovative and significant therapeutic alternatives for individuals affected by HIV.
• In Sept. 2021, ViiV Healthcare and Shionogi signed an exclusive licence agreement for the development of ultra-long-acting, third-generation HIV integrase inhibitors. According to the provisions of the agreement, ViiV Healthcare will pay Shionogi £20 Bn upfront, £15 Bn upon the achievement of a clinical development milestone, and royalties on net sales.

Segmentation of Integrase Inhibitors Market-
By Drug Class-
• First-Generation Integrase Inhibitors
• Second-Generation Integrase Inhibitors
• Others
By Indication-
• HIV Infection
• Other Indications
By Distribution Channel-
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By End User-
• Hospitals and Clinics
• Research Institutes
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2089

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Integrase Inhibitors Market Top Players - Gilead Sciences, ViiV Healthcare, Merck & Co., Inc., GlaxoSmithKline PLC. here

News-ID: 3793527 • Views:

More Releases from Insightace Analytic Pvt Ltd.

T-cell Lymphoma Market Exclusive Report on Current Trends and Future Insights
T-cell Lymphoma Market Exclusive Report on Current Trends and Future Insights
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global T-cell Lymphoma Market By Lymphoma Type (Peripheral T-Cell Lymphoma (Cutaneous T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-Immuno-Blastic T-Cell Lymphoma, And Others (Intestinal T-Cell Lymphoma, Follicular T-Cell Lymphoma)) And T-Cell Lymphoblastic Lymphoma), Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, And Others (Antiviral Treatment, Etc.)- Trends, Industry Competition Analysis, Revenue and Forecast To 2034." According to the
Sprycel Market is on an Upward Growth Curve
Sprycel Market is on an Upward Growth Curve
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Sprycel Market- (By Demographic (Age, Gender, Income), By Psychographic (Lifestyle, Attitudes), By Behavioral, (Usage Rate, Compliance, Treatment), By Medical (Indication, Disease Stage)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Sprycel Market is valued at US$ 5.47 Bn in 2022, and it is expected to
Spatial Omics Solutions Market Report- Expansive Coverage on the Profit Sources
Spatial Omics Solutions Market Report- Expansive Coverage on the Profit Sources
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Spatial Omics Solutions Market By Solution Type (Instruments, Consumables And Services), Sample Analyzed (DNA, RNA, And Protein Samples), Application (Diagnosis, Translation Research, Drug Discovery And Development, Single Cell Analysis, Cell Biology And Other Applications), End-User Segment (Academic And Research Institutions, Biopharmaceutical And Biotechnological Companies, Contract Research Organizations And Other)- Trends, Industry Competition Analysis, Revenue and
Psoriasis Biosimilars Market Future Trends and Scope Analysis Report
Psoriasis Biosimilars Market Future Trends and Scope Analysis Report
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Psoriasis Biosimilars Market - (By Drug Class (TNF-alpha inhibitors (Infliximab, Etanercept, Adalimumab), Other biosimilars), By Route of Administration (Subcutaneous, Intravenous, Oral, Topical), By Indication (Plaque psoriasis, Psoriatic arthritis, Other types), By Distribution Channel (Hospital pharmacies, Retail pharmacy chains, Online pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce

All 5 Releases


More Releases for Integrase

Integrase Inhibitors Market Report: Insights, Analysis & Opportunities to 2032 | …
The qualitative latest Research report (2025-2032) on the Integrase Inhibitors Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves. Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/6023 Focused on growth and
Global Integrase Inhibitors Market Outlook 2025-2034: Trends, Innovations, And F …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics. What Is the Integrase Inhibitors Market Size and Projected Growth Rate? The market size for integrase inhibitors has witnessed significant growth in the past few years. It is projected to rise from $4.40 billion in 2024 to $4.71 billion in 2025, marking a compound annual growth rate (CAGR) of 6.9%. The impressive progress in
Integrase Inhibitors Market Key Players Analysis - Gilead Sciences, ViiV Healthc …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Integrase Inhibitors Market- (By Drug Class (First-Generation Integrase Inhibitors, Second-Generation Integrase Inhibitors, Others), By Indication (HIV Infection, Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals and Clinics, Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global
Integrase Inhibitors Market to Reach USD 24.22 Billion by 2032, Posting a CAGR o …
Integrase Inhibitors Market is estimated to be valued at USD 16.43 Bn in 2025 and is expected to reach USD 24.22 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032. A recent market research report by Coherent Market Insights provides a detailed analysis of the Integrase Inhibitors Market from 2025 to 2032. The report delivers precise global and regional market forecasts, offering actionable
Integrase Inhibitors Market Latest Report with Forecast to 2031
Integrase Inhibitors Market worth $40.56 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Integrase Inhibitors Market- (By Drug Class (First-Generation Integrase Inhibitors, Second-Generation Integrase Inhibitors, Others), By Indication (HIV Infection, Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals and Clinics, Research Institutes, Others)), Trends, Industry Competition
HIV Integrase Strand Transfer Inhibitors INSTI Market Is Expected Significant Gr …
HIV Integrase Strand Transfer Inhibitors INSTI Market Outlook (2022-2029) The Global HIV Integrase Strand Transfer Inhibitors INSTI Market 2029 Industry Report is a professional and in-depth study of the current state of the HIV Integrase Strand Transfer Inhibitors INSTI Market by SMI. The HIV Integrase Strand Transfer Inhibitors INSTI Market is supposed to demonstrate considerable growth during the forecast period of 2022 - 2029. The company profiles of all the key